Mapping new pharmacological interventions for cognitive function in Alzheimer’s disease: a systematic review of randomized clinical trials
Background and Objective: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, that is, characterized by cognitive decline. To date, there are no effective treatments for AD. Therefore, the objective of this study was to map new perspectives on the effects of pharmacological treatme...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-06-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1190604/full |
| _version_ | 1797814301618077696 |
|---|---|
| author | Inmaculada Xu Lou Inmaculada Xu Lou Jiayue Chen Jiayue Chen Kamran Ali Abdul Lateef Shaikh Qilan Chen |
| author_facet | Inmaculada Xu Lou Inmaculada Xu Lou Jiayue Chen Jiayue Chen Kamran Ali Abdul Lateef Shaikh Qilan Chen |
| author_sort | Inmaculada Xu Lou |
| collection | DOAJ |
| description | Background and Objective: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, that is, characterized by cognitive decline. To date, there are no effective treatments for AD. Therefore, the objective of this study was to map new perspectives on the effects of pharmacological treatment on cognitive function and the overall psychological state in patients with AD.Methods: Two independent researchers searched for randomized clinical trials (RCTs) exploring new pharmacological approaches related to cognition in Alzheimer’s disease in adults from 2018 to 2023 in PubMed, Web of Science, Scopus, and Cochrane Library databases. A total of 17 RCTs were included in this review.Results: The results show that in recent years, new drugs have been tested in patients with Alzheimer’s disease, including masitinib, methylphenidate, levetiracetam, Jiannao Yizhi, and Huannao Yicong formulas. Most studies have been conducted in populations with mild to moderate Alzheimer’s disease.Conclusion: Although some of the drugs found suggested improvement in cognitive function, the scarcity of available studies highlights the need for further research in this area.Systematic review registration: [www.crd.york.ac.uk/prospero], identifier [CRD42023409986]. |
| first_indexed | 2024-03-13T08:05:37Z |
| format | Article |
| id | doaj.art-ce6ebe71b15b4aeeaeca2b3a9d6bd8e7 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-13T08:05:37Z |
| publishDate | 2023-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-ce6ebe71b15b4aeeaeca2b3a9d6bd8e72023-06-01T05:19:51ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-06-011410.3389/fphar.2023.11906041190604Mapping new pharmacological interventions for cognitive function in Alzheimer’s disease: a systematic review of randomized clinical trialsInmaculada Xu Lou0Inmaculada Xu Lou1Jiayue Chen2Jiayue Chen3Kamran Ali4Abdul Lateef Shaikh5Qilan Chen6International Education College of Zhejiang Chinese Medical University, Hangzhou, ChinaDepartment of Cardiology, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, ChinaDepartment of Cardiology, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, ChinaHangzhou Clinical Medical College Internal Medicine of Traditional Chinese Medicine of Zhejiang Chinese Medical University, Hangzhou, ChinaDepartment of Oncology, The Fourth Affiliated Hospital, International Institutes of Medicine, Zhejiang University School of Medicine, Yiwu, ChinaKey Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaDepartment of Cardiology, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, ChinaBackground and Objective: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, that is, characterized by cognitive decline. To date, there are no effective treatments for AD. Therefore, the objective of this study was to map new perspectives on the effects of pharmacological treatment on cognitive function and the overall psychological state in patients with AD.Methods: Two independent researchers searched for randomized clinical trials (RCTs) exploring new pharmacological approaches related to cognition in Alzheimer’s disease in adults from 2018 to 2023 in PubMed, Web of Science, Scopus, and Cochrane Library databases. A total of 17 RCTs were included in this review.Results: The results show that in recent years, new drugs have been tested in patients with Alzheimer’s disease, including masitinib, methylphenidate, levetiracetam, Jiannao Yizhi, and Huannao Yicong formulas. Most studies have been conducted in populations with mild to moderate Alzheimer’s disease.Conclusion: Although some of the drugs found suggested improvement in cognitive function, the scarcity of available studies highlights the need for further research in this area.Systematic review registration: [www.crd.york.ac.uk/prospero], identifier [CRD42023409986].https://www.frontiersin.org/articles/10.3389/fphar.2023.1190604/fullAlzheimer diseasecognitionpharmacologytreatmentlatest researchbeta-amyloid |
| spellingShingle | Inmaculada Xu Lou Inmaculada Xu Lou Jiayue Chen Jiayue Chen Kamran Ali Abdul Lateef Shaikh Qilan Chen Mapping new pharmacological interventions for cognitive function in Alzheimer’s disease: a systematic review of randomized clinical trials Frontiers in Pharmacology Alzheimer disease cognition pharmacology treatment latest research beta-amyloid |
| title | Mapping new pharmacological interventions for cognitive function in Alzheimer’s disease: a systematic review of randomized clinical trials |
| title_full | Mapping new pharmacological interventions for cognitive function in Alzheimer’s disease: a systematic review of randomized clinical trials |
| title_fullStr | Mapping new pharmacological interventions for cognitive function in Alzheimer’s disease: a systematic review of randomized clinical trials |
| title_full_unstemmed | Mapping new pharmacological interventions for cognitive function in Alzheimer’s disease: a systematic review of randomized clinical trials |
| title_short | Mapping new pharmacological interventions for cognitive function in Alzheimer’s disease: a systematic review of randomized clinical trials |
| title_sort | mapping new pharmacological interventions for cognitive function in alzheimer s disease a systematic review of randomized clinical trials |
| topic | Alzheimer disease cognition pharmacology treatment latest research beta-amyloid |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1190604/full |
| work_keys_str_mv | AT inmaculadaxulou mappingnewpharmacologicalinterventionsforcognitivefunctioninalzheimersdiseaseasystematicreviewofrandomizedclinicaltrials AT inmaculadaxulou mappingnewpharmacologicalinterventionsforcognitivefunctioninalzheimersdiseaseasystematicreviewofrandomizedclinicaltrials AT jiayuechen mappingnewpharmacologicalinterventionsforcognitivefunctioninalzheimersdiseaseasystematicreviewofrandomizedclinicaltrials AT jiayuechen mappingnewpharmacologicalinterventionsforcognitivefunctioninalzheimersdiseaseasystematicreviewofrandomizedclinicaltrials AT kamranali mappingnewpharmacologicalinterventionsforcognitivefunctioninalzheimersdiseaseasystematicreviewofrandomizedclinicaltrials AT abdullateefshaikh mappingnewpharmacologicalinterventionsforcognitivefunctioninalzheimersdiseaseasystematicreviewofrandomizedclinicaltrials AT qilanchen mappingnewpharmacologicalinterventionsforcognitivefunctioninalzheimersdiseaseasystematicreviewofrandomizedclinicaltrials |